OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making
Nassim Djebli, Vincent Buchheit, Neil Parrott, et al.
European Journal of Drug Metabolism and Pharmacokinetics (2021) Vol. 46, Iss. 6, pp. 779-791
Closed Access | Times Cited: 11
Nassim Djebli, Vincent Buchheit, Neil Parrott, et al.
European Journal of Drug Metabolism and Pharmacokinetics (2021) Vol. 46, Iss. 6, pp. 779-791
Closed Access | Times Cited: 11
Showing 11 citing articles:
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
Ami V. Desai, Giles Robinson, Karen Gauvain, et al.
Neuro-Oncology (2022) Vol. 24, Iss. 10, pp. 1776-1789
Open Access | Times Cited: 71
Ami V. Desai, Giles Robinson, Karen Gauvain, et al.
Neuro-Oncology (2022) Vol. 24, Iss. 10, pp. 1776-1789
Open Access | Times Cited: 71
Entrectinib, a new multi-target inhibitor for cancer therapy
Qinghua Jiang, Mingxue Li, Hua Li, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 150, pp. 112974-112974
Open Access | Times Cited: 51
Qinghua Jiang, Mingxue Li, Hua Li, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 150, pp. 112974-112974
Open Access | Times Cited: 51
Clinical Exploration and Physiologically Based Modelling of the Impact of Hepatic Impairment on Entrectinib Pharmacokinetics
Agustos C. Ozbey, Georgina Meneses‐Lorente, Brian Simmons, et al.
Clinical Pharmacokinetics (2025)
Closed Access
Agustos C. Ozbey, Georgina Meneses‐Lorente, Brian Simmons, et al.
Clinical Pharmacokinetics (2025)
Closed Access
MIDD in Japan– Implementations, challenges and opportunities
Mayumi Hasegawa, Shinichi Kijima
Advanced Drug Delivery Reviews (2025), pp. 115553-115553
Closed Access
Mayumi Hasegawa, Shinichi Kijima
Advanced Drug Delivery Reviews (2025), pp. 115553-115553
Closed Access
Simultaneous Estimation of fm and FG Values Directly from Clinical Drug-Drug Interaction Study Data
Yumi Cleary, Nicoló Milani, Kayode Ogungbenro, et al.
The AAPS Journal (2025) Vol. 27, Iss. 4
Open Access
Yumi Cleary, Nicoló Milani, Kayode Ogungbenro, et al.
The AAPS Journal (2025) Vol. 27, Iss. 4
Open Access
Optimizing Zanubrutinib Dosing in Patients: A PBPK‐BO Model Approach to Drug–Drug Interactions and Patients with Hepatic Impairment
Jiawei Ren, Dan Shan, Guijuan Yue, et al.
The Journal of Clinical Pharmacology (2025)
Closed Access
Jiawei Ren, Dan Shan, Guijuan Yue, et al.
The Journal of Clinical Pharmacology (2025)
Closed Access
Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug–drug interaction studies
Jayaprakasam Bolleddula, Sathej Gopalakrishnan, Ping Hu, et al.
Clinical and Translational Science (2022) Vol. 15, Iss. 9, pp. 2075-2095
Open Access | Times Cited: 17
Jayaprakasam Bolleddula, Sathej Gopalakrishnan, Ping Hu, et al.
Clinical and Translational Science (2022) Vol. 15, Iss. 9, pp. 2075-2095
Open Access | Times Cited: 17
Kenichi Umehara, Neil Parrott, Emilie Schindler, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 4, pp. 1130-1140
Closed Access | Times Cited: 3
Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL ‐6 levels following administration of the T‐cell bispecific engager glofitamab
Nassim Djebli, Neil Parrott, Félix Jaminion, et al.
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 13, Iss. 3, pp. 396-409
Open Access | Times Cited: 7
Nassim Djebli, Neil Parrott, Félix Jaminion, et al.
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 13, Iss. 3, pp. 396-409
Open Access | Times Cited: 7
Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs
Xiaowen Wang, Fang Chen, Nan Guo, et al.
Cancer Chemotherapy and Pharmacology (2023) Vol. 92, Iss. 4, pp. 253-270
Closed Access | Times Cited: 5
Xiaowen Wang, Fang Chen, Nan Guo, et al.
Cancer Chemotherapy and Pharmacology (2023) Vol. 92, Iss. 4, pp. 253-270
Closed Access | Times Cited: 5
Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working Group
Wenkui Li, Faye Vazvaei‐Smith, Gordon J. Dear, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 115, Iss. 5, pp. 939-953
Open Access | Times Cited: 4
Wenkui Li, Faye Vazvaei‐Smith, Gordon J. Dear, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 115, Iss. 5, pp. 939-953
Open Access | Times Cited: 4
Prediction of ROS1 and TRKA/B/C occupancy in plasma and cerebrospinal fluid for entrectinib alone and in DDIs using physiologically based pharmacokinetic (PBPK) modeling approach
Liangang Chen, Na Yao, Hongjie Yang, et al.
Cancer Chemotherapy and Pharmacology (2023) Vol. 93, Iss. 2, pp. 107-119
Closed Access | Times Cited: 3
Liangang Chen, Na Yao, Hongjie Yang, et al.
Cancer Chemotherapy and Pharmacology (2023) Vol. 93, Iss. 2, pp. 107-119
Closed Access | Times Cited: 3
Development and Validation of an Ecofriendly, Rapid, Simple and Sensitive UPLC-MS/MS Method for Entrectinib Quantification in Plasma for Therapeutic Drug Monitoring
Essam A. Ali, Muzaffar Iqbal, G. Mostafa, et al.
Separations (2023) Vol. 10, Iss. 9, pp. 494-494
Open Access
Essam A. Ali, Muzaffar Iqbal, G. Mostafa, et al.
Separations (2023) Vol. 10, Iss. 9, pp. 494-494
Open Access
